Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer

BACKGROUND: The efficacy and safety of naldemedine (a peripherally acting µ-opioid receptor antagonist) for opioid-induced constipation (OIC) in subjects with cancer was demonstrated in the primary report of a phase III, double-blind study (COMPOSE-4) and its open-label extension (COMPOSE-5). The pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Katakami, N, Harada, T, Murata, T, Shinozaki, K, Tsutsumi, M, Yokota, T, Arai, M, Tada, Y, Narabayashi, M, Boku, N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005145/
https://www.ncbi.nlm.nih.gov/pubmed/32151367
http://dx.doi.org/10.1093/annonc/mdy118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005145/
https://www.ncbi.nlm.nih.gov/pubmed/32151367
http://dx.doi.org/10.1093/annonc/mdy118

Ejemplares similares